메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

LabConnect Partners with Kits4Life to Reduce Kit Waste and…

JOHNSON CITY, Tenn., Aug. 8, 2025 -- As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership with Kits4Life, an initiative of the MedSurplus Alliance. This collaboration reflects our broader ESG strategy and strengthens LabConnect's role as the world's most agile and responsible central laboratory services provider. Through this partnership, LabConnect will work with sponsors and clinical sites to identify and manage eligible kits for donation, reducing landfill waste while
- 김갑성 기자
- 2025-08-08 00:40
Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Fin…

SHANGHAI, Aug. 7, 2025 -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led by Qiming Venture Partners. Further support came from existing investor TF Capital, and seven new investors, including including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's Board of Directors. Proceeds will be used to advance the company
- 김갑성 기자
- 2025-08-07 18:00
US NCI Sponsors Senhwa Biosciences' Second Program-IND…

TAIPEI and SAN DIEGO, Aug. 7, 2025 -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National Cancer Institute (NCI) sponsors Senhwa's second program IND has been submitted to US FDA for clinical trial targeting MYC-aberrant lymphoma. Following the initiation of the first trial using CX-5461 as a monotherapy in advanced solid tumors, the IND-submission of the second trial marks a milestone in the development of CX-5461. With
- 김갑성 기자
- 2025-08-07 14:35
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Dis…

Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine. The collaboration, worth up to $5.99 billion, represents one of the largest commitments to date for
- 김갑성 기자
- 2025-08-07 08:05
US Air Force Awards Gastops $18.6M Contract for ChipCHECK Oil D…

HUNTSVILLE, Ala., Aug. 7, 2025 -- Gastops USA has been awarded an $18.6 million follow-on contract by the U.S. Air Force to supply its advanced ChipCHECK Portable Debris Analyzer, enhancing front-line maintenance capabilities for jet engines. This contract provides for the procurement of 145 ChipCHECK units, enabling field-based analysis of metallic debris in aircraft engine oil—specifically targeting the F110 engine that powers the F-15 Eagle and F-16 Fighting Falcon fighter aircraft. It follows the successful research, development, and commercialization of ChipCHECK through the Small
- 김갑성 기자
- 2025-08-07 01:07
FDA approves expanded indication for AVTOZMA® (tocilizuma…

Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine release syndrome (CRS) [1] AVTOMZA received FDA approval in January 2025, for multiple inflammatory indications including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19) in IV formulation [1] INCHEON, South Korea, Aug. 6, 2025 -- Celltrion, Inc. today announced that
- 김갑성 기자
- 2025-08-06 20:00
Continuity Biosciences Appoints Josephine Torrente and…

BRADENTON, Fla., Aug. 6, 2025 -- Continuity Biosciences, a company pioneering next-generation combination product drug delivery, today announced the appointment of two highly distinguished leaders to its Board of Directors: Josephine M. Torrente, Director at Hyman, Phelps & McNamara, P.C., and Dr. Joseph M. DeSimone, serial entrepreneur and professor at Stanford University. These appointments mark a significant step forward in Continuity's mission to advance transformative drug delivery technologies, supported by world-class regulatory expertise and materials science innovation.&n
- 김갑성 기자
- 2025-08-06 20:00
컨티뉴이티 바이오사이언스, 이사회에 조세핀 토렌테, 조지프 디시몬 영입

브레이든턴, 플로리다, 2025년 8월 6일 -- 차세대 복합 약물 전달 분야의 선도 기업인 컨티뉴이티 바이오사이언스(Continuity Biosciences)가 이사회에 두 명의 저명한 인사를 영입했다고 발표했다. 새로 합류한 인사는 조세핀 M. 토렌테(Josephine M. Torrente) 하이먼, 펠프스 & 맥나마라(Hyman, Phelps & McNamara, P.C.) 이사와 조지프 M. 디시몬(Dr. Joseph M. DeSimone) 스탠퍼드대학교 교수이자 연쇄 창업가다. 이번 선임은 세계적인 규제 전문성과 재료과학 혁신을 바탕으로 혁신적인 약물 전달 기술을 발전시키려는 콘티뉴이티의 사명에 있어 중요한 진전으로 평가된다. 조세핀 M. 토렌테 현직: 미국 최대 규모의 FDA 규제 전문 법률 회사인 하이먼, 펠프스 & 맥나마라(Hyman, Phelps & McNamara, P.C.) 이사 경력: 30년 이상 제약 및 바이오 기업을 대상으로 FDA 규제 전략, 제품 개발, 전주기 관리 등에 대해 자문 전략적 기여: 토렌테 이사의 깊이 있는 규제 통찰력을 통해 회사가
- 김갑성 기자
- 2025-08-06 20:00
The U.S. FDA Granted Fast Track Designation to Dizal's Birelen…

Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pretreated CLL/SLL patients SHANGHAI, Aug. 6, 2025 -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its Birelentinib (DZD8586) for the treatment
- 김갑성 기자
- 2025-08-06 19:02
Ductal Carcinoma In Situ Discovery from Gynecomastia Surgery…

[ 메디채널 김갑성 기자 ] Gynecomastia can indicate underlying health concerns, including cancer, and surgery provides an opportunity to examine tissues for abnormalities. Early detection saves lives. SINGAPORE, Aug. 6, 2025 -- Dr Ivan Puah, an MOH-accredited liposuction doctor at Amaris B. Clinic, with decades of experience in male chest contouring and gynecomastia surgery, emphasises the critical significance of adhering to rigorous surgical protocols and conducting comprehensive diagnostics. This includes the essential practice of sending every case of gynecomastia surgery for thorough hist
- 김갑성 기자
- 2025-08-06 17:28

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분